Medios AGMEDOF 88 3-Year ROIIC % is 2.20 as of Dec. 2025, which is 11% below its 10-year median of 2.48. GuruFocus rates MEDOF with a GF Score™ of 88/100 and a GF Value™ of $71.50. The stock has 2 warning signs investors should review. Among 113 Medical Distribution companies, Medios AG ranks worse than 50.44% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Medios AG's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 2.20%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Medios AG's 3-Year ROIIC % or its related term are showing as below:
MEDOF's 3-Year ROIIC % is ranked worse than 50.44% of 113
companies
in the Medical Distribution industry
Industry Median: 2.2
vs MEDOF: 2.20
Medios AG (OTCPK:MEDOF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Medios AG 3-Year ROIIC % Related Terms
Medios AG 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Medios AG's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Medios AG's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medios AG 3-Year ROIIC % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medios AG's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Medios AG's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Medios AG (MEDOF) has a 3-Year ROIIC % of 2.20 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medios AG and its competitors. This is 11% below median its historical median of 2.48. According to the industry distribution chart, Medios AG ranks #57 out of 113 companies in the Medical Distribution industry, placing it in the top 50.4%.
Is Medios AG's 3-Year ROIIC % too high?
Medios AG's current 3-Year ROIIC % of 2.20 is 11% below median its 10-year median of 2.48. The Medical Distribution industry median 3-Year ROIIC % is 2.20. Medios AG's value of 2.20 is 0% at this industry median. Based on the distribution chart, Medios AG ranks #57 out of 113 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Medios AG has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Medios AG's 3-Year ROIIC % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Medios AG ranks #57 out of 113 companies for 3-Year ROIIC %. This places Medios AG in the lower half of its industry. The industry median 3-Year ROIIC % is 2.20. Medios AG's value of 2.20 is 0% at this benchmark. While the company's 10-year median is 2.48 vs. the industry median of 2.20, Medios AG has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Distribution company?
The median 3-Year ROIIC % among Medical Distribution companies is 2.20, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medios AG's current 3-Year ROIIC % of 2.20 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medios AG and its competitors. For the Medical Distribution industry, the median 3-Year ROIIC % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medios AG's current 3-Year ROIIC % is 2.20, which is 11% below median its own 10-year median of 2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medios AG stock overvalued right now?
Medios AG (MEDOF) has a current 3-Year ROIIC % of 2.20. The stock's GF Value™ is $71.50, compared to a current price of $50.00 — trading 30.1% below its estimated fair value. The current 3-Year ROIIC % is 2.20, which is 11% below median its 10-year median of 2.48 and 0% at the Medical Distribution industry median of 2.20. Medios AG's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Medios AG (MEDOF), the current 3-Year ROIIC % is 2.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medios AG (MEDOF) Overvalued in 2026?
Based on GuruFocus' analysis, Medios AG stock appears to be undervalued.
The current stock price of $50.00 is trading 30.1% below its estimated GF Value™ of $71.50.
Key valuation signals for MEDOF:
3-Year ROIIC %: 2.20 (11% below median its 10-year median of 2.48)
GF Value™: $71.50 vs. price of $50.00 (30.1% below fair value)
Industry Position: 0% at the Medical Distribution median (#57 of 113)
No single metric tells the full story. See the MEDOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medios AG is engaged as a wholesaler for pharmaceutical medicinal products. The operating segments of the company includes: Patient-Specific Therapies: This area includes the compounding of medications on behalf of pharmacies in Germany. Pharmaceautical Supply: Medios is speciality pharma supplier company in germany, producing it own production facilities, hospitals, and Pharmacies. International Business: It includes all business and activities happening in international business.
88GF Score
Get the complete analysis for MEDOF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDOF has been successfully added to your 
